copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
Trials Archive - Cholangiocarcinoma Foundation A phase II study of pemigatinib plus durvalumab (MEDI4736) in previously treated advanced intrahepatic cholangiocarcinoma patients with FGFR-2 fusion or rearrangement
Cholangiocarcinoma (Bile Duct Cancer) Clinical Trials - Mayo Clinic . . . ABC-108 is a single-arm Phase IIA clinical study of ABC294640 (Yeliva ®) in the treatment of cholangiocarcinoma (CCA) In this clinical study, all participants will be receiving ABC294640 The study drug, ABC294640 is an orally available inhibitor of the enzyme sphingosine kinase-2 (SK2)
Intrahepatic Cholangiocarcinoma - Intera Oncology A single-arm, prospective, phase II trial showed a median overall survival of 25 months and a 1-year survival rate of 89%, a dramatic improvement in overall survival, independent of resectability for unresectable iCCA patients treated with HAI therapy
Intrahepatic Cholangiocarcinoma clinical trials This study is a single-arm Phase II clinical trial aiming to evaluate the safety and efficacy of HAIC combined with Cadonilimab and Regorafenib as second-line treatment for unresectable intrahepatic cholangiocarcinoma
Cholangiocarcinoma Clinical Trials - Rare Disease Advisor CCA is classified as intrahepatic (iCCA) or extrahepatic (eCCA), according to the anatomical location; eCCA is further subclassified as perihilar (pCCA) or distal (dCCA) 1,2 Despite diagnostic and therapeutic advancements, the prognosis for patients with advanced CCA remains poor, with 5-year overall survival rates of 8% for iCCA and 10% for
ClinConnect | Intrahepatic Cholangiocarcinoma (Icc) Find 13 active clinical trials for intrahepatic cholangiocarcinoma (icc) Discover research opportunities, treatment options, and connect with medical studies in your area Join the fight against intrahepatic cholangiocarcinoma (icc)
What new research is being done in bile duct cancer treatment? | MD . . . Javle will present Phase II clinical trial results at the 2023 European Society for Medical Oncology (ESMO) Congress The drug being studied in the clinical trial, tinengotinib, is an example of a next-generation FGFR inhibitor because it binds to the FGFR2 in a unique way